Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Brickell Biotech stock price, quote, forecast and news

BBI
US10802T1051
A2PRDX

Price

2.23
Today +/-
+0
Today %
+0 %
P

Brickell Biotech stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Brickell Biotech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Brickell Biotech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Brickell Biotech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Brickell Biotech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Brickell Biotech Stock Price History

DateBrickell Biotech Price
9/9/20222.23 undefined
9/8/20222.12 undefined

Brickell Biotech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Brickell Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Brickell Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Brickell Biotech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Brickell Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Brickell Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Brickell Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Brickell Biotech’s growth potential.

Brickell Biotech Revenue, EBIT and net profit per share

DateBrickell Biotech RevenueBrickell Biotech EBITBrickell Biotech Net Income
2026e11.62 M undefined-24.23 M undefined-494,427.98 undefined
2025e8.91 M undefined-25.05 M undefined-485,973.8 undefined
2024e6.91 M undefined-26.16 M undefined-482,440.83 undefined
2023e3.83 M undefined-27.12 M undefined-509,243.13 undefined
20226.94 M undefined-21.53 M undefined-21.1 M undefined
2021404,000 undefined-40.24 M undefined-39.47 M undefined
20201.82 M undefined-20.98 M undefined-20.91 M undefined
20197.92 M undefined-19.67 M undefined-13.6 M undefined
20181.62 M undefined-18.26 M undefined-16.25 M undefined
201713.82 M undefined-13.39 M undefined-12.96 M undefined
201614.53 M undefined-9.18 M undefined-8.97 M undefined
201520.95 M undefined-9.4 M undefined-9.24 M undefined
201415.22 M undefined-16.63 M undefined-16.49 M undefined
20137.72 M undefined-31.35 M undefined-31.24 M undefined
201217.52 M undefined-23.43 M undefined-22.9 M undefined
201130.02 M undefined-7.82 M undefined-7.28 M undefined
20108.71 M undefined-31.22 M undefined-30.39 M undefined
200912.69 M undefined-28.59 M undefined-28.56 M undefined
20087.96 M undefined-36.74 M undefined-36.9 M undefined
20075.51 M undefined-40.26 M undefined-35.89 M undefined
200614.74 M undefined-26.42 M undefined-23.15 M undefined
200512 M undefined-25.65 M undefined-24.36 M undefined
200414.55 M undefined-25.14 M undefined-23.73 M undefined
20038.08 M undefined-25.63 M undefined-24.45 M undefined

Brickell Biotech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e
00112355667510711781412145712830177152014131710636811
----100.0050.0066.67-20.00-16.67-28.57100.00-30.0057.14-36.3614.2975.00-14.2916.67-64.2940.0071.43-33.33275.00-43.33-58.82114.2933.33-30.00-7.14-92.31600.00-85.71---50.00100.0033.3337.50
-----------------14.29-7.14-160.00-42.8616.67-25.0063.3323.53-57.1426.6750.0057.1453.85---------
00000000000000000201-8-32-2194-441087000000000
0-1-2-1-2-2-2-5-5-7-7-9-9-16-17-27-25-25-25-26-40-36-28-31-7-23-31-16-9-9-13-18-19-20-40-21-27-26-25-24
---200.00-100.00-100.00-66.67-40.00-100.00-83.33-116.67-100.00-180.00-90.00-228.57-154.55-385.71-312.50-178.57-208.33-185.71-800.00-514.29-233.33-387.50-23.33-135.29-442.86-106.67-45.00-64.29-100.00-1,800.00-271.43-2,000.00--350.00-900.00-433.33-312.50-218.18
0-1-2-1-2-1-1-4-3-5-5-7-6-8-9-27-24-23-24-23-35-36-28-30-7-22-31-16-9-8-12-16-13-20-39-210000
--100.00-50.00100.00-50.00-300.00-25.0066.67-40.00-14.2933.3312.50200.00-11.11-4.174.35-4.1752.172.86-22.227.14-76.67214.2940.91-48.39-43.75-11.1150.0033.33-18.7553.8595.00-46.15----
0.070.080.090.110.120.120.160.180.190.220.220.230.230.280.290.290.290.320.350.450.560.570.670.861.031.231.241.271.310.030.040.070.070.541.782.810000
----------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Brickell Biotech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Brickell Biotech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                                                 
2.50.510.132.527.352.546.845.640.237.7148.1134.1109.282.271.36497.968.833.544.352.447.480.850.44436.735.6260.548.0711.7330.1226.888.68
0.10.20.50.60.60.51.91.61.444.44.65.94.73.45.851.31.91.30.93.12.24.64.24.53.425.120.030000
000000000000000000000000000000000
000000000000000000000000000000000
0000000000002.32.42.72.42.52.72.82.82.933.13.13.23.28.8210.691.16.243.422.721.4
2.60.710.633.127.95348.747.241.641.7152.5138.7117.489.377.472.2105.472.838.248.456.253.586.158.151.444.447.8776.3249.217.9733.5329.610.08
10.80.60.810.72.32.21.71.93.55.14.91516.315.213.512.310.79.37.66.25.33.92.61.91.170.610.10.180.10.120.12
0000000000550.8000005.45.55.45.92.2222.12.052.212.390000
0000000000000000000000000000000064
0.40.70.40.60.70.81.11.21.41.41.65.45.65.95.85.55.24.94.33.73.22.92.821.71.30.810.700000
000000000000000000000000000000000
0.30.30.30.50.80.50.30.10.10.10.20.30.60.61.81.61.10.70.50.50.50.20.20.40.40.20.390.660.660000
1.71.81.31.92.523.73.53.23.410.315.811.921.523.922.319.817.920.91916.715.210.58.36.75.54.424.183.150.180.10.120.19
4.32.511.93530.45552.450.744.845.1162.8154.5129.3110.8101.394.5125.290.759.167.472.968.796.666.458.149.952.2880.4952.3418.1433.6329.7210.27
                                                                 
0.10.10.10.10.10.20.20.20.20.20.20.20.20.20.20.30.40.40.40.50.70.70.90.90.90.90.110.220.220.090.541.190.03
8.78.719.244.244.272.772.977.378.383.3203.1203.5203.6203.6221.3243299.6301.5307.1341.3380.9384.1435.9439.7446.7449.3458.88489.98490.3492.5132.49169.08173.63
-5.6-7.9-9.9-11.2-15.6-19.6-24.6-30.3-37.7-44.6-53.2-62.4-90.3-114.8-138.5-162.9-186-221.9-258.8-287.4-317.8-325-347.9-379.2-395.7-404.9-413.88-426.74-442.06-84.98-105.89-145.37-166.47
00-900-600-900-10000100-100700800900800-200-100200-100050050060020000025122272-28000
000000000000000000000000000000000
3.20.98.532.527.853.248.547.240.938.8150.8142.1114.489.882.880.3114.279.948.754.964.360.489.161.451.945.345.1463.5848.767.5727.1324.917.19
000000.10.10.30.80.20.100.40.40.60.30.50.60.710.80.40.40.40.20.70.331.210.412.250.571.610.57
00000000.30.621.71.83.61.210.70.44.95.47.15.665.33.153.23.843.146.465.493.212.51
0.30.72.61.511.11.811.12.74.24.44.96.43.93.74.52.11.7200.10.20.200.33.0211.70.031.8000
00000000000000000000000000000029100
0.40.30.20.30.40.30.50.70.70.70.91.51.94.34.64.12.70.60.200000000000000
0.712.81.81.41.52.42.33.25.66.97.710.812.310.18.88.18.2810.16.46.55.93.75.24.27.1516.923.5810.56.354.813.08
0.30.30.30.40.50.31.61.20.80.72.12.62.37.25.83.40.70.20000000000000.1500
000000000000000000000000000000000
00000000003221.52.422.32.42.52.42.221.71.30.90.40000.07000
0.30.30.30.40.50.31.61.20.80.75.14.64.38.78.25.432.62.52.42.221.71.30.90.40000.070.1500
11.33.12.21.91.843.546.31212.315.12118.314.211.110.810.512.58.68.57.656.14.67.1516.923.5810.576.54.813.08
4.22.211.634.729.75552.550.744.945.1162.8154.4129.5110.8101.194.5125.390.759.267.472.968.996.766.45849.952.2880.4952.3418.1433.6329.7210.27
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Brickell Biotech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Brickell Biotech's financial health and stability.

Assets

Brickell Biotech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Brickell Biotech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Brickell Biotech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Brickell Biotech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-2-1-2-1-1-4-3-5-5-7-6-8-9-27-24-23-24-23-35-36-28-30-7-22-31-16-9-8-12-16-23-20-39-21
0000000000111233333222222111000000
0000000000000000000000000000000000
1001-1000010-1-11-1-1-22602-3-20-51-1-123-13-100
00000000000004000213123343210-11232
0000000000000000000000000000000000
0000000000000000000000000000000000
-1-1-10-1-3-3-4-4-5-6-8-8-19-21-21-22-15-24-30-21-28-3-17-29-9-6-8-8-14-35-20-36-19
0000000-1000-1-5-1-12-4-2-1-1-1000-10000000000
0000-315-199060-106359-17-6-214215-912-5-2625-120-7-5132400
0000-316-1911160-10441111112-4-194416-813-4-2525-120-7-5132400
0000000000000000000000000000000000
0000000000000-17-3-3-4-2000000000002000
23092502804141190001721550333370480307300038331
12092402803041200-17141750-2332370480307300238321
----------------------------------
0000000000000000000000000000000000
01-19-814501-2527-11-161-111315-11221-84-4-18-6-816-13022-3-18
000000000000000000000000000-8.64-8.68-14.48-35.99-20.06-36.18-19.38
0000000000000000000000000000000000

Brickell Biotech stock margins

The Brickell Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Brickell Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Brickell Biotech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Brickell Biotech's sales revenue. A higher gross margin percentage indicates that the Brickell Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Brickell Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Brickell Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Brickell Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Brickell Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Brickell Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Brickell Biotech Margin History

Brickell Biotech Gross marginBrickell Biotech Profit marginBrickell Biotech EBIT marginBrickell Biotech Profit margin
2026e56.78 %-208.57 %-4.26 %
2025e56.78 %-281.06 %-5.45 %
2024e56.78 %-378.74 %-6.98 %
2023e56.78 %-708.05 %-13.29 %
202256.78 %-310.15 %-303.93 %
202156.78 %-9,961.39 %-9,770.79 %
202056.78 %-1,151.26 %-1,147.8 %
201956.78 %-248.43 %-171.82 %
201856.78 %-1,125.46 %-1,002.1 %
201753.12 %-96.87 %-93.78 %
201656.71 %-63.15 %-61.75 %
201547.83 %-44.87 %-44.11 %
201428.84 %-109.26 %-108.34 %
2013-64.51 %-406.09 %-404.66 %
201225.46 %-133.73 %-130.71 %
201165.79 %-26.05 %-24.25 %
2010-31.34 %-358.44 %-348.91 %
200918.36 %-225.3 %-225.06 %
2008-38.82 %-461.56 %-463.57 %
2007-149.73 %-730.67 %-651.36 %
20067.8 %-179.24 %-157.06 %
2005-1.67 %-213.75 %-203 %
200420.34 %-172.78 %-163.09 %
2003-4.95 %-317.2 %-302.6 %

Brickell Biotech Stock Sales Revenue, EBIT, Earnings per Share

The Brickell Biotech earnings per share therefore indicates how much revenue Brickell Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Brickell Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Brickell Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Brickell Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Brickell Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Brickell Biotech Revenue, EBIT and net profit per share

DateBrickell Biotech Sales per ShareBrickell Biotech EBIT per shareBrickell Biotech Earnings per Share
2026e4.38 undefined0 undefined-0.19 undefined
2025e3.36 undefined0 undefined-0.18 undefined
2024e2.6 undefined0 undefined-0.18 undefined
2023e1.44 undefined0 undefined-0.19 undefined
20222.47 undefined-7.67 undefined-7.51 undefined
20210.23 undefined-22.55 undefined-22.12 undefined
20203.34 undefined-38.51 undefined-38.39 undefined
2019117.87 undefined-292.81 undefined-202.52 undefined
201823.4 undefined-263.31 undefined-234.44 undefined
2017337.79 undefined-327.21 undefined-316.79 undefined
2016456.95 undefined-288.58 undefined-282.17 undefined
201515.99 undefined-7.18 undefined-7.05 undefined
201411.98 undefined-13.09 undefined-12.98 undefined
20136.23 undefined-25.28 undefined-25.19 undefined
201214.24 undefined-19.05 undefined-18.62 undefined
201129.15 undefined-7.59 undefined-7.07 undefined
201010.13 undefined-36.3 undefined-35.34 undefined
200918.94 undefined-42.67 undefined-42.63 undefined
200813.96 undefined-64.46 undefined-64.74 undefined
20079.84 undefined-71.89 undefined-64.09 undefined
200632.76 undefined-58.71 undefined-51.44 undefined
200534.29 undefined-73.29 undefined-69.6 undefined
200445.47 undefined-78.56 undefined-74.16 undefined
200327.86 undefined-88.38 undefined-84.31 undefined

Brickell Biotech business model

Brickell Biotech Inc is a biopharmaceutical company that focuses on the development and marketing of innovative dermatology products. The company was founded in 2009 and is headquartered in Boulder, Colorado (USA), with branches in California and Singapore. The history of Brickell Biotech dates back to the 1960s when the company was originally founded under the name Brickell Research Inc. Over the following decades, the company specialized in biological research and conducted important research that forms the basis for today's product development. Brickell Biotech's business model is based on the creation of new and innovative therapies for the treatment of various dermatological diseases. In recent years, the company has entered into a number of important partnerships to accelerate its product development and strengthen its position in the industry. Brickell Biotech operates in two main areas: pharmaceuticals and cosmetic products. In the pharmaceuticals area, the company has a number of promising therapies in the pipeline that target the treatment of skin cancer, psoriasis, and other dermatological conditions. The company's flagship product is Sofpironium Bromide, a potential treatment for hyperhidrosis (excessive sweating). In the cosmetic products area, the company has developed a range of skincare products tailored to the needs of people with sensitive, dry, or aging skin. These products include moisturizers, cleansers, and anti-aging products, all made from high-quality ingredients. Brickell Biotech works closely with the scientific community to explore the latest developments and innovations in dermatology and the cosmetics industry. The company has also established a strong presence in the medical and research sectors by collaborating closely with leading universities and medical institutions worldwide. Overall, Brickell Biotech is a promising company in the biopharmaceutical and cosmetics industry, specializing in the development of new and innovative therapies for the treatment of skin conditions. With a strong pipeline of products and a dedicated leadership team, the company is expected to continue growing and establish itself as an important player in the industry. Brickell Biotech is one of the most popular companies on Eulerpool.com.

Brickell Biotech SWOT Analysis

Strengths

1. Strong research and development capabilities, enabling the company to develop innovative biotech products.

2. Established reputation and expertise in the biotech industry.

3. Strong financial position and a solid balance sheet, providing stability and potential for growth.

4. Robust intellectual property portfolio, protecting the company's innovations and providing a competitive edge.

Weaknesses

1. Reliance on a limited product portfolio, which may expose the company to market fluctuations and competition.

2. Limited global presence and market reach, limiting potential growth opportunities.

3. High research and development costs, which may impact profitability in the short term.

Opportunities

1. Growing demand for biotech products and therapies, presenting opportunities for market expansion.

2. Increasing adoption of personalized medicine, offering potential for customized biotech solutions.

3. Potential partnerships and collaborations with established pharmaceutical companies, enabling access to larger markets and resources.

Threats

1. Intense competition within the biotech industry, posing a challenge to market share and pricing strategies.

2. Stringent regulatory requirements and lengthy approval processes, potentially delaying product launches.

3. Rapid technological advancements, leading to the emergence of substitute products or more efficient alternatives.

Brickell Biotech Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Brickell Biotech historical P/E ratio, EBIT, and P/S ratio.

Brickell Biotech shares outstanding

The number of shares was Brickell Biotech in 2023 — This indicates how many shares 2.808 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Brickell Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Brickell Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Brickell Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Brickell Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Brickell Biotech Stock splits

In Brickell Biotech's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Brickell Biotech.

Brickell Biotech list of shareholders

%
Name
Stocks
Change
Date
5.10399 % Ionic Ventures LLC135,444-26,46912/31/2021
3.18899 % Medical Strategy GmbH84,62603/31/2022
2.60611 % The Vanguard Group, Inc.69,1588,9183/31/2022
1.59536 % Telemetry Investments, L.L.C.42,336-13,9523/31/2022
1.18876 % Renaissance Technologies LLC31,546-35,9053/31/2022
0.82067 % Palisade Capital Management, LLC21,7782106/9/2022
0.64084 % Hardy (Reginald L)17,00606/9/2022
0.52531 % Geode Capital Management, L.L.C.13,94003/31/2022
0.26518 % Brown (Robert Busard)7,03706/9/2022
0.18062 % BlackRock Institutional Trust Company, N.A.4,79303/31/2022
1
2
3
4
5
...
7

Brickell Biotech Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Kaken Pharmaceutical Stock
Kaken Pharmaceutical
SupplierCustomer0,720,860,270,140,880,31
Carna Biosciences Stock
Carna Biosciences
SupplierCustomer-0,190,820,730,270,780,72
AnGes Stock
AnGes
SupplierCustomer-0,45-0,320,060,250,980,72
1

Most common questions regarding Brickell Biotech

What values and corporate philosophy does Brickell Biotech represent?

Brickell Biotech Inc represents values of innovation, integrity, and dedication to improving patient lives. With a strong corporate philosophy focused on developing transformative therapeutics, Brickell Biotech is dedicated to advancing dermatology solutions for unmet medical needs. The company's commitment to excellence is reflected in its research and development efforts to bring novel treatments to market. Brickell Biotech's approach emphasizes collaboration, leveraging scientific expertise, and fostering strong relationships with healthcare professionals. By prioritizing patient well-being and employing cutting-edge technologies, Brickell Biotech Inc strives to make a positive impact on the lives of individuals with dermatological conditions.

In which countries and regions is Brickell Biotech primarily present?

Brickell Biotech Inc is primarily present in the United States.

What significant milestones has the company Brickell Biotech achieved?

Brickell Biotech Inc has achieved significant milestones in its journey. These include the FDA approval of its novel therapeutic, sofpironium bromide gel, for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweating. This milestone demonstrates the company's commitment to addressing unmet medical needs. Furthermore, Brickell Biotech Inc has successfully completed Phase 3 clinical trials, showcasing the efficacy and safety of its product. The company's achievements reflect its dedication to developing innovative solutions to improve patients' quality of life. Brickell Biotech Inc's FDA approval and completion of pivotal trials signify substantial progress towards becoming a leading pharmaceutical player in the dermatology market.

What is the history and background of the company Brickell Biotech?

Brickell Biotech Inc is a pharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in 2009, Brickell Biotech has established a strong presence in the dermatology and infectious disease markets. With a mission to improve patients' lives, the company focuses on developing novel treatments addressing unmet medical needs. Brickell Biotech has a rich history of successful research and development, collaborating with leading clinicians and scientists. Its dedication to innovation and commitment to quality has positioned the company as a trusted healthcare partner. Brickell Biotech's continuous efforts in advancing medical solutions highlight its dedication to improving global health.

Who are the main competitors of Brickell Biotech in the market?

The main competitors of Brickell Biotech Inc in the market are other pharmaceutical companies that focus on the development and commercialization of novel therapeutics. These may include companies such as Johnson & Johnson, Pfizer, Merck & Co., Inc., Bristol Myers Squibb, and Novartis.

In which industries is Brickell Biotech primarily active?

Brickell Biotech Inc is primarily active in the healthcare and pharmaceutical industries. As a leading company in the field, Brickell Biotech focuses on the development and commercialization of innovative therapeutics for the treatment of various skin diseases, such as hyperhidrosis and acne. With its cutting-edge research and advanced formulations, Brickell Biotech aims to provide effective solutions that improve the lives of patients worldwide. By revolutionizing the dermatological market, Brickell Biotech Inc continues to establish itself as a key player in the healthcare industry, delivering innovative products backed by scientific expertise and a commitment to patient care.

What is the business model of Brickell Biotech?

Brickell Biotech Inc's business model focuses on the development and commercialization of innovative therapeutics for various skin conditions. With a strong emphasis on dermatology, the company aims to address unmet medical needs through cutting-edge research and development. By harnessing its proprietary delivery technologies and expertise in drug development, Brickell Biotech Inc strives to bring novel treatment options to patients suffering from conditions like hyperhidrosis and other dermatologic disorders. The company's commitment to advancing scientific knowledge and delivering effective therapies underscores its mission to improve patients' lives and enhance skin health.

What is the P/E ratio of Brickell Biotech 2024?

The Brickell Biotech P/E ratio is -12.98.

What is the P/S ratio of Brickell Biotech 2024?

The Brickell Biotech P/S ratio is 0.91.

What is the AlleAktien quality score of Brickell Biotech?

The AlleAktien quality score for Brickell Biotech is 2/10.

What is the revenue of Brickell Biotech 2024?

The expected Brickell Biotech revenue is 6.91 M USD.

How high is the profit of Brickell Biotech 2024?

The expected Brickell Biotech profit is -482,440.83 USD.

What is the business model of Brickell Biotech

Brickell Biotech Inc is an American biopharmaceutical company specializing in the development of products for the treatment of skin disorders. The company was founded in 2009 and is headquartered in Boulder, Colorado.

What is the Brickell Biotech dividend?

Brickell Biotech pays a dividend of 0 USD distributed over payouts per year.

How often does Brickell Biotech pay dividends?

The dividend cannot currently be calculated for Brickell Biotech or the company does not pay out a dividend.

What is the Brickell Biotech ISIN?

The ISIN of Brickell Biotech is US10802T1051.

What is the Brickell Biotech WKN?

The WKN of Brickell Biotech is A2PRDX.

What is the Brickell Biotech ticker?

The ticker of Brickell Biotech is BBI.

How much dividend does Brickell Biotech pay?

Over the past 12 months, Brickell Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Brickell Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Brickell Biotech?

The current dividend yield of Brickell Biotech is .

When does Brickell Biotech pay dividends?

Brickell Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Brickell Biotech?

Brickell Biotech paid dividends every year for the past 0 years.

What is the dividend of Brickell Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Brickell Biotech located?

Brickell Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Brickell Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Brickell Biotech from 9/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did Brickell Biotech pay the last dividend?

The last dividend was paid out on 9/12/2024.

What was the dividend of Brickell Biotech in the year 2023?

In the year 2023, Brickell Biotech distributed 0 USD as dividends.

In which currency does Brickell Biotech pay out the dividend?

The dividends of Brickell Biotech are distributed in USD.

All fundamentals about Brickell Biotech

Our stock analysis for Brickell Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Brickell Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.